Navigation Links
Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Date:5/27/2009

SAN DIEGO, May 27 /PRNewswire/ -- Verus Pharmaceuticals, Inc. ("Verus"), a specialty pharmaceutical company, announced today that it has filed a lawsuit against AstraZeneca AB ("AstraZeneca") and Tika Lakemedel AB ("Tika") in the Supreme Court of the State of New York, in which it is seeking $1.3 billion on claims of fraud, breach of contract, and conversion. Verus claims that AstraZeneca and its wholly owned subsidiary Tika disregarded their obligations under three agreements with Verus, entered into in 2007, pursuant to which the defendants were to pursue the research and development of Verus' assets, including budesonide, a steroid for the treatment of pediatric asthma in the United States. Verus further alleges that defendants' representations that induced Verus to enter into the agreements constituted fraud.

About Verus

Verus is dedicated to improving the lives of children and those who care for them. More information about Verus is available on the company's corporate website at www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company Contact:
    Blair C. Fensterstock, Esq.,
    Managing Director
    Fensterstock & Partners LLP
    BFensterstock@fensterstock.com
    212-785-4100 Office; 917-689-1137 Cell


'/>"/>
SOURCE Verus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adolescent Growth Plate Injuries May Be Related to Overuse
2. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
3. Kids Overuse Sports Injuries Are on the Rise
4. Study Asks: Are Physicians Overusing an Invasive Cardiac Treatment?
5. Urgent need for research into the best treatment for medication overuse headaches
6. Verus Pharmaceuticals Announces Divestiture of Pediatric GI Development Program to Meritage Pharma
7. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
8. ReachMD and VerusMed Broadcast Medical Conference Coverage on XM Satellite Radio
9. Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
10. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
11. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin ... new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved ... who play in the wet and early morning dew or right after a rain shower, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, serving ... a new charity campaign. As part of their ongoing community involvement program, funds ... belief that children deserve a voice, and in the spirit of neighbors helping ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: